3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
165
Polycystic Ovary Syndrome
23
Neoplasm Metastasis
9
Osteoporosis
7
Neoplasms
6
Infertility
6
Endometrial Neoplasms
5
Carcinoma, Intraductal, Noninfiltrating
5
Ovarian Neoplasms
4
Breast Carcinoma In Situ
4
Arthralgia
4
Hereditary Sensory and Autonomic Neuropathies
3
Carcinoma, Ductal, Breast
3
Breast Neoplasms, Male
3
Breast Cancer Metastatic
3
Advanced Breast Cancer
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Pain
2
Leiomyoma
2
Fallopian Tube Neoplasms
2
Estrogen Receptor-positive Breast Cancer
2
Carcinoma, Lobular
2
Bone Diseases, Metabolic
2
Uterine Neoplasms
1
Patient Acceptance of Health Care
1
Ovarian Cysts
1
Osteitis Deformans
1
Obesity
1
Neoplastic Cells, Circulating
1
Interventions
Sirolimus
6
Everolimus
5
saracatinib
1
nintedanib
1
Urination
1
Sugars
1
Simvastatin
1
Resveratrol
1
Octreotide
1
Letrozole
1
Imatinib Mesylate
1
Hydroxychloroquine
1
Glutamine
1
Doxycycline
1
Celecoxib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphangioleiomyomatosis
×
Letrozole
×
Clear all
NCT01353209
2024-04-17
TRAIL
University of Cincinnati
Phase 2
Completed
17 enrolled
13 charts